Profile data is unavailable for this security.
About the company
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
- Revenue in USD (TTM)0.00
- Net income in USD-7.18m
- Incorporated2015
- Employees3.00
- LocationAvenue Therapeutics Inc1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS 33154United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (302) 531-3150
- Websitehttps://avenuetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals Inc | 378.20k | -1.07m | 3.39m | 2.00 | -- | -- | -- | 8.96 | -0.1563 | -0.1563 | 0.0564 | 0.6121 | 0.0474 | 0.8827 | 1.90 | 126,066.70 | -9.87 | -- | -- | -- | -23.45 | -- | -208.43 | -- | 6.77 | -- | 0.0217 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
| Aditxt Inc | 4.03m | -31.57m | 3.48m | 47.00 | -- | -- | -- | 0.8637 | -100.82 | -100.82 | 0.4992 | -- | -- | -- | -- | 85,739.79 | -- | -192.78 | -- | -321.59 | 68.67 | -- | -774.60 | -7,208.65 | -- | -3.75 | -- | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Axim Biotechnologies Inc | 39.77k | -8.06m | 3.50m | 6.00 | -- | -- | -- | 87.94 | -0.0366 | -0.0366 | 0.0001 | -0.0311 | 0.0095 | -- | -- | 6,628.33 | -193.43 | -154.34 | -- | -390.73 | -- | -- | -20,265.75 | -36,362.71 | -- | -0.62 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -106.25m | 3.51m | 7.00 | -- | 0.1537 | -- | -- | -1,922.89 | -1,922.89 | 0.00 | 27.33 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.89m | 3.53m | 21.00 | -- | 0.9444 | -- | -- | -1.26 | -1.26 | 0.00 | 0.3388 | 0.00 | -- | -- | 0.00 | -168.89 | -132.00 | -228.29 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Sonoma Pharmaceuticals Inc | 12.31m | -5.08m | 3.54m | 9.00 | -- | 0.4642 | -- | 0.2878 | -0.9608 | -0.9608 | 1.95 | 0.489 | 0.8625 | 2.58 | 4.76 | 1,367,778.00 | -35.56 | -37.52 | -47.14 | -51.35 | 39.17 | 40.17 | -41.23 | -37.12 | 3.11 | -- | 0.0065 | -- | 5.10 | -4.44 | -1.28 | -- | 7.54 | -- |
| Onconetix Inc | 58.47k | -37.41m | 3.55m | 12.00 | -- | -- | -- | 60.68 | -2.09 | -2.09 | 0.0034 | 2.63 | 0.001 | -- | 0.6301 | 4,872.50 | -65.73 | -- | -87.29 | -- | -1,927.76 | -- | -63,981.00 | -- | 0.3185 | -19.88 | 0.1292 | -- | -- | -- | -176.78 | -- | -- | -- |
| AccuStem Sciences Inc | 0.00 | -2.05m | 3.57m | 3.00 | -- | -- | -- | -- | -0.1807 | -0.1807 | 0.00 | -0.1861 | 0.00 | -- | -- | 0.00 | -382.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 45.26 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -7.18m | 3.59m | 3.00 | -- | 0.7929 | -- | -- | -39.36 | -39.36 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -123.08 | -186.91 | -1,045.52 | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -13.96m | 3.59m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -16.28m | 3.60m | 18.00 | -- | 0.1889 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Target Group Inc | 5.64m | 228.87k | 3.64m | 46.00 | 45.38 | -- | 3.42 | 0.6455 | 0.0001 | 0.0001 | 0.0088 | -0.0115 | 0.764 | 8.60 | 124.27 | 115,104.10 | 3.10 | -37.99 | -- | -78.76 | 43.71 | -- | 4.06 | -586.97 | 0.0736 | 0.0149 | 3.10 | -- | -- | 577.83 | 92.84 | -- | -58.54 | -- |
| Atreca Inc | 0.00 | -97.76m | 3.65m | 90.00 | -- | 0.3388 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
| Geovax Labs Inc | 0.00 | -27.78m | 3.76m | 17.00 | -- | 69.32 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Seelos Therapeutics Inc | 1.97m | -27.12m | 3.79m | 10.00 | -- | -- | -- | 1.92 | -44.59 | -44.59 | 2.16 | -17.36 | 0.1449 | -- | 2.24 | 131,600.00 | -198.99 | -180.05 | -- | -386.76 | -- | -- | -1,373.61 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to Avenue Therapeutics Inc's reporting currency: US Dollar USD
2.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Mar 2024 | 8.95k | 1.50% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 2.37k | 0.40% |
| G1 Execution Services LLCas of 31 Mar 2024 | 959.00 | 0.16% |
| Geode Capital Management LLCas of 31 Mar 2024 | 695.00 | 0.12% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 617.00 | 0.10% |
| HRT Financial LLCas of 31 Mar 2024 | 616.00 | 0.10% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 408.00 | 0.07% |
| Jane Street Capital LLCas of 31 Mar 2024 | 399.00 | 0.07% |
| Millennium Management LLCas of 31 Mar 2024 | 140.00 | 0.02% |
| Tower Research Capital LLCas of 31 Mar 2024 | 118.00 | 0.02% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
